Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is a promising gene therapy company with a strong focus on developing treatments for various genetic and other diseases. The collaboration with Bristol Myers Squibb for cardiovascular diseases, as well as their pipeline programs for Huntington's Disease, Temporal Lobe Epilepsy, Fabry Disease, ALS, and Hemophilia B, show a diverse and promising portfolio. With the anticipated BLA filing for AMT-130 in the third quarter of 2026 and the expected commercial launch in the third quarter of 2027, followed by a potential ex-U.S. launch in 2027, we have increased our confidence in the commercial potential of their lead program and have raised our AMT-130 probability of success to 85%. However, risks to achieving our $80 price target include clinical development, commercialization, reimbursement, capital markets and dilution, pricing, and clinical trial risks.

Bears say

uniQure is facing potential delays in their product launch due to the FDA's stricter regulatory standards, indicated by the recent departure of key FDA personnel. Additionally, their financials are uncertain due to unpredictable future revenues and stock price volatility. Furthermore, their UK commercial planning may not be as advanced as previously thought, posing potential challenges for bringing their gene therapy to market.

uniQure (QURE) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 12 analysts, uniQure (QURE) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.